I-Study Think Tank #2: Towards a System Plan for Transformation of Cancer Care to a Molecular-Based Approach through Genomics

EVENT DETAILS :

Start Date:May 30, 2013
End Date: May 30, 2013
Start Time: EST
End Time: EST
Location:
Email:webinars@onemillionsolutionsinhealth.org
Register

Event organised by Dawn Van Dam (Executive Director of One Million Solutions in Health)

I-Study Think Tank #2: Towards a System Plan for Transformation of Cancer Care to a Molecular-Based Approach through Genomics

Following its landmark industry study on the advance of genomics into healthcare, Cambridge Healthtech Associates (CHA) conducted an industry Think Tank: Towards a System Plan for Transformation of Cancer Care to a Molecular-Based Approach through Genomics.

This invitation-only, high-level event took place in Chicago, before ASCO on May 30, 2013, and was keynoted by Dr. Richard Wilson, Director of the Genome Institute at Washington University School of Medicine. The event was a combination of keynotes and interactive sessions, and concluded with a set of clear industry recommendations and action plans – developed by session participants.

The original I-Study panel wrote: Most interviewees feel that cancer is best treated as a molecular disorder and not an organ disorder. There is growing frustration with the present mismatch between this inevitable approach, and the organ-based structure of the present healthcare system. We urge cancer associations to prepare a system plan for this transformation of cancer to recognize that cancer mutates and is more similar across organs than previously understood.

Participants at the I-Study Think Tank were called on to be inspirational and to be inspired by the thought leaders, visionaries and industry luminaries who were present at this event. CHA will publish the group’s recommendations to help jump-start our collective efforts in ‘Big Data for Genomic Healthcare’.

We strictly limited attendance at this Think Tank to senior-level executives from academic, government, not-for-profit and industry organizations. That is, only those who have the ability and the power to ‘take action’ and move their organizations in new directions. Appropriate titles, of course, were: C-level, President, General Manager, Senior VP, Vice President, Senior Director, Board Member, etc.

KEYNOTE AND WORKSHOP TOPICS

1. The New Cancer Care Flowchart and Division of Work (Keynote)

In treating cancer as a molecular disorder, what are the updated responsibilities and connections for the entire care team — physicians, oncologists, geneticists, genomics teams, payors, foundations, patients and researchers?

2. The Risk Assessment/Prevention Phase: The New Assignments and Learning
Specifically in the Risk Assessment/Prevention phase, what are the new assignments in the care team and what new/continued learning is required to be successful in these updated roles?

3. The Detection Phase: The New Learning and Assignments
Specifically in the Detection phase, what are the new assignments in the care team and what new/continued learning is required to be successful in these updated roles?

4. The Treatment/Prognosis Phase: The New Learning and Assignments
Specifically in the Treatment/Prognosis phase, what are the new assignments in the care team and what new/continued learning is required to be successful in these updated roles?

5. Which Genomic Challenges are Most Pressing
Beyond the system of care, the list of fundamental genomic challenges in front of routine, molecular-based cancer care is significant. It includes: deeper research, sharing data/findings, incorporating outcomes, defining and providing evidence, genotyped clinical trials, payor support and integrated analysis. Which are most pressing and addressable in the near-term?

6. Innovative Ideas/Approaches to Accelerate the Advance
What are some innovative ideas to address some of the fundamental issues in topics 1-6, and accelerate the advance of genomics into routine cancer care?

7. Which Organizations Should Carry this Forward and How
How best should the cancer care community carry these important ideas/plans forward? What recommendations do we have for representative organizations?

VIEW THE FULL AGENDA

DISCUSSION LEADERS

	Richard Wilson, PhD (Keynote Speaker) Director, The Genome Center Washington University School of Medicine		Nickolas Papadopoulos, PhD Director, Translational Genetics Johns Hopkins Ludwig Center
	Nazneen Aziz, PhD Director, Molecular Medicine College of American Pathologists		Peter Pitts, PhD President and CoFounder Center for Medicine in the Public Interest
	Judy Garber, MD MPH Director, Cancer Risk and Prevention Clinic Dana-Farber Cancer Institute		Paula Rieger, RN, MSN Chief Executive Officer Oncology Nursing Society
	Timothy McDaniel, PhD Director, Scientific Research Illumina		Shashikant Kulkarni, PhD Head of Clinical Genomics Washington University School of Medicine
	Les Paul, MD MS Senior Vice President and Chief Medical Officer Caris Life Sciences		Shyamali Singhal, MD PhD Medical Director, Cancer Center El Camino Hospital
	Mary Zutter, MD Assistant Vice Chancellor for Integrative Diagnostics Vanderbilt University Medical Center		John Sweetenham, MD Senior Director, Clinical Affairs and Executive Medical Director Huntsman Cancer Institute